Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: bioengineering

Check out our new promo for #transvision #future Summit 2021! Get your tickets! -> www.TransVisionMadrid.com There will be talks about #longevity #artificialintelligence #cryonics and much much more. You will also be able to network with speakers and attendees during 5 optional dinner/cocktails, and 2 tours of several UNESCO heritage sites and historical places: Ávila, Segovia, Monsaterio de El Escorial, Valle de los Caídos (Valley of the Fallen), Aranjuez & Toledo.

Humanity Plus Humanity Plus Humanity Plus Magazine MUTISHAN Interactive Vivian Francos #SEOHashtag Alcor Life Extension Foundation Cryonics Institute Cryonics Institute SENS Research Foundation SENS Research Foundation Posthuman Network Posthuman Network Cryonics4U Longevity Conferences Longevity for All U.S. Transhumanist Party Transhumanist Party Australia Transhumanist Party Virtual Rational Transhumanism Singularity University Ray Kurzweil Singularity Singularity Hub Ray Kurzweil’s Singularity Singularity Network Transhumanismo Brasil Transhumanismo Brasil TRANSHUMANISMO Christian Transhumanist Association Mormon Transhumanist Association SingularityNET Singularitarianism Foresight Institute Lifeboat Foundation Lifeboat Foundation Machine Intelligence Research Institute KrioRus The Hedonistic Imperative — Paradise Engineering.

Promo by sergio tarrero for alianza futurista & transvision madrid.

http://www.TransVisionMadrid.com.

Spain will host the next world futurist summit on October 8, 9 and 10, 2021. Humanity+ will be the main international organizer of this international congress. Afterwards, during October 11 and 12, we will continue with informal conversations while traveling to UNESCO World Heritage Sites around Madrid: Aranjuez, Ávila, El Escorial, Segovia y Toledo. Every night will finish with optional cocktails in beautiful places for networking and meeting the participants and speakers.

The topics covered will be very broad, from recent medical advances, to artificial intelligence and robotics. The first keynote speakers will be the world famous Ray Kurzweil and Aubrey de Gray. Additionally, TransVision 2021 will feature other keynote presentations, such as those from futurist movement pioneers Max More, Natasha Vita-More and Ben Goertzel, members of Humanity+ and other leading institutions.

#TransVision collaborates with leading organizations working on futurist concepts such as life extension, artificial intelligence, robotics, nanotechnology, space travel, human enhancement, blockchain and other future technologies and trends. The first TransVision conference was held in 1998 in the Netherlands, and since there we have hosted 14 international summits in cities like Berlin, Brussels, Caracas, Chicago, Helsinki, London, Madrid, Milano, Paris, Stockholm and Toronto.

Read more | >

One of the scientists prodding and poking the Kelly brothers is Prof Christopher E Mason, the lead geneticist on the Twins Study. Mason’s lab at Cornell University is nothing if not ambitious. Its work centres on a “500-year plan for the survival of the human species on Earth, in space, and on other planets.”

As well as studying what happens to astronauts, it involves laying the genetic groundwork for humans to live among the stars. Mason envisions a future in which the human genome can be bioengineered to adapt to almost any environment, augmented with genes from other species that allow us to explore and settle the farthest corners of the Universe.

Read more | >

We probably at this point should make all animals immortal: 3.

The advance promises to unlock new insights into human biology and disease, aiding in the study of everything from the developing immune system to tissue regeneration to skin cancer.

“Studying biodiversity is not just about exploring the biology of a bunch of interesting organisms, but ultimately for a better understanding of human biology,” developmental biologist and lead study author Hiroshi Kiyonari said via email.

Five years ago, his team began to systematically work out the problem that had so long plagued the opossum field. The first barrier was to collect zygotes (fertilized eggs) at the right time. Ideally, that would be before they began dividing, when they are still a single cell. If you inject CRISPR at this stage, you can be sure all the resulting animals’ cells will carry whatever DNA changes you make. Doing it later can mean some cells but not others will be edited — a less ideal outcome known as mosaicism. Another benefit of collecting fertilized eggs as early as possible is that the shell coat hasn’t had time to thicken.

Read more | >

In this video, Drs Irina and Mike Conboy talk about their theory of why we age and introduce Neutral Blood Exchange, which came from their original parabiosis experiments documented in a 2005 paper.

Our guests today are Drs. Irina and Michael Conboy of the Department of Bioengineering at the University of California Berkeley. their discovery of the rejuvenating effects of young blood through parabiosis in a seminal paper published in Nature in 2005 paved the way for a thriving field of rejuvenation biology. The Conboy lab currently focuses on broad rejuvenation of tissue maintenance and repair, stem cell niche engineering, elucidating the mechanisms underlying muscle stem cell aging, directed organogenesis, and making CRISPR a therapeutic reality.

Papers mentioned in this video.
Plasma dilution improves cognition and attenuates neuroinflammation in old mice.
https://pubmed.ncbi.nlm.nih.gov/33191466/
Rejuvenation of three germ layers tissues by exchanging old blood plasma with saline-albumin.
https://pubmed.ncbi.nlm.nih.gov/32474458/
Rejuvenation of aged progenitor cells by exposure to a young systemic environment.
https://pubmed.ncbi.nlm.nih.gov/15716955/

************************************************************
Health claims Disclosure: Information provided on this video is not a substitute for direct, individual medical treatment or advice. Please consult with your doctor first. Products or services mentioned in this video are not a recommendation.

Disclosure: Some of the links provided are affiliate links. Although we may receive a small commission from the affiliate, the cost of the product for you will always be the same, or often discounted. Thank you for supporting our channel.

Audio Copyright Disclaimer:
Please note that we have full authorization to the music that we used in our videos as they were created using the service WeVideo which provides the rights to the music. The rights are detailed in the terms of use that can be reviewed here https://www.wevideo.com/terms-of-use and any following inquiries should be addressed to [email protected].
*****************************************************************
If you would like to support our channel, we’d love a coffee…thank you! https://www.buymeacoffee.com/mhealthspan

Read more | >

Replacing Aging — Dr. Jean M. Hebert, Ph.D. Albert Einstein College of Medicine.

Dr. Jean M. Hebert, Ph.D. (https://einsteinmed.org/faculty/9069/jean-hebert/) is Professor in the Department of Genetics and in the Dominick P. Purpura Department of Neuroscience, at Albert Einstein College of Medicine.

He’s also the author of the book Replacing Aging, which describes how regenerative medicine will beat aging.

With a Ph.D. in Genetics from the University of California, San Francisco, Dr. Hebert’s current lab’s projects fall into two groups.

First, they focus on using the mouse neocortex as a platform for testing the ability of multi-cell type grafts (increasingly resembling normal neocortex) to integrate with host tissue.

Secondly, they are testing the ability of genetically engineered microglia that disperse throughout the adult neocortex to bolster neocortical function.

These highly collaborative projects require a range of multidisciplinary methods, including molecular genetics, human embryonic stem cell biology, transcriptomics, surgery, electrophysiology, live brain imaging, and behavioral tests, among others.

Read more | >

“Prime Editing is a wonderful example of the revolution in genetic medicine that we are living through,” said Robert Nelsen, co-founder and Managing Director of ARCH Venture Partners, one of several companies to fund Prime Medicine. “Gene editing technologies like this, when mature, could totally change our conception of what’s possible in treating disease.”

“This is an opportunity to take a giant step toward cures for a much wider range of diseases than previously possible,” said Stephen Knight, President and Managing Partner of F-Prime Capital, another backer of the new company.

The funds raised will be used to continue building the company, expand the capabilities of its technology platform and rapidly advance towards clinical indications. By the end of 2021, Prime Medicine expects to employ more than 100 people full-time.

Read more | >

Investing in the convergence of bioelectrics & biologics for regeneration & healing — howard J. leonhardt, founder, leonhardt ventures.

Howard Leonhardt is the Founder of Leonhardt Ventures, the world’s first Innovation Accelerator focused on the convergence of bioelectrics & biologics for organ regeneration and tissue healing.

Howard is an accomplished inventor and serial entrepreneur, with 21 U.S. patents, over 100 patent claims for products for treating cardiovascular disease, and has over 40 new patent claims pending. His TALENT (Taheri-Leonhardt) stent graft, developed in the early 1990′s, holds a leading world market share for repairing aortic aneurysms without surgery.

Howard’s inventions to date have been involved in treated over 500000 patients in 60 countries.

Howard is co-leader of Startup California and Founder and Chairman of The California Stock Exchange TM (Cal-X) preparing to be the first social good impact stock exchange currently operating the Cal-X 30 Social Good Impact fund. He founded Cal-X Crowdfund Connect, a crowdfunding campaign management company, and Cal-X Stars Business Accelerator, Inc., a business incubator and accelerator focused on cardiovascular life sciences and social good impact innovations.

There are 30 regenerative med-tech and regenerative economy startups in his current portfolio. His Leonhardt Ventures angels network has raised and put to work over US$145 million in 32 companies to date, including those developing the first implantable programmable and re-fillable stem cell pump, brain, eye, and aorta regeneration technologies, and number of other organ regeneration spin offs from his patented core technologies.

Howard Leonhardt serves as state spokesperson in California for the JOBS ACT and Crowdfunding for Startup California and has given over 40 speeches on the subject. He has operated Leonhardt’s Launchpads NorCal at the University of Northern California Science & Technology Innovation Center in Rohnert Park, CA since 2008 and recently opened Leonhardt’s Launchpads Utah in Salt Lake City just off the campus of the University of Utah. He has served on the Board of Directors of the University of Northern California, a private biomedical engineering school, since 1999.

Read more | >

University of California San Diego scientists have now developed several genetic editing tools that help pave the way to an eventual gene drive designed to stop Culex mosquitoes from spreading disease. Gene drives are designed to spread modified genes, in this case those that disable the ability to transmit pathogens, throughout the targeted wild population.

Genetics toolkit targets less researched Culex mosquitoes, which transmit West Nile virus and avian malaria.

Since the onset of the CRISPR genetic editing revolution, scientists have been working to leverage the technology in the development of gene drives that target pathogen-spreading mosquitoes such as Anopheles and Aedes species, which spread malaria, dengue, and other life-threatening diseases.

Much less genetic engineering has been devoted to Culex genus mosquitoes, which spread devastating afflictions stemming from West Nile virus—the leading cause of mosquito-borne disease in the continental United States—as well as other viruses such as the Japanese encephalitis virus (JEV) and the pathogen causing avian malaria, a threat to Hawaiian birds.

Read more | >

Here is a snapshot of our talks on synthetic biology. These videos will provide you with a basic understanding and appreciation for this field. These lectures start with an introduction to synthetic biology and go through the major discoveries and ethical controversies that arise from this field. You can check out the full Synthetic Biology Playlist here!

Read more | >

Breast cancer is the leading cause of cancer death in women around the world, responsible for 1700 deaths every day. Although the vast majority of breast cancers are treatable, the most aggressive subtype—triple negative breast cancer (TNBC) – has a high recurrence rate, a high potential for metastasis and shows resistance to conventional treatments, leading to very poor prognosis and survival outcomes. A team of researchers at the Research Institute of the McGill University Health Center (RI-MUHC) conducted a preclinical study and discovered a novel targeted combination therapy that efficiently reduced tumor growth in metastatic breast cancer. Published in Nature Communications, their findings could lead to the development of a novel first line targeted therapy for the treatment of TNBC, with the prospect of rapidly transitioning to clinical trials in humans.

“There is no targeted therapy for TNBC. Chemotherapy treatment can even enrich these tumors in and be detrimental to the patient, as we have shown in a previous study,” says Dr. Jean-Jacques Lebrun, senior scientist in the Cancer Research Program at the RI-MUHC and principal investigator of the study. “Filling that huge medical gap was our motivation in conducting this study.”

While most breast cancers have one of three main receptors that are like entrance gates for treatments—estrogen, progesterone and a protein called human epidermal growth factor (HER2) – TNBC has none, thus the name triple negative . Using state-of-the-art technologies such as and genome-wide molecular approaches, the team identified two pathways which could be targeted in a therapeutic strategy.

Read more | >